ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $1,253,000 | -2.7% | 10,674 | +11.5% | 0.02% | -4.3% |
| Q4 2021 | $1,288,000 | -14.8% | 9,576 | +0.9% | 0.02% | -14.8% |
| Q3 2021 | $1,512,000 | +13.2% | 9,488 | -6.6% | 0.03% | +3.8% |
| Q2 2021 | $1,336,000 | +12.6% | 10,159 | +10.3% | 0.03% | 0.0% |
| Q1 2021 | $1,187,000 | +4.0% | 9,212 | +34.7% | 0.03% | -7.1% |
| Q4 2020 | $1,141,000 | +189.6% | 6,841 | +95.6% | 0.03% | -6.7% |
| Q1 2020 | $394,000 | -46.7% | 3,497 | -34.1% | 0.03% | +50.0% |
| Q4 2019 | $739,000 | +45.2% | 5,309 | +18.9% | 0.02% | +5.3% |
| Q2 2019 | $509,000 | +6.7% | 4,466 | +10.3% | 0.02% | -5.0% |
| Q1 2019 | $477,000 | +61.1% | 4,049 | -14.3% | 0.02% | +53.8% |
| Q4 2018 | $296,000 | -13.7% | 4,722 | -2.4% | 0.01% | -7.1% |
| Q3 2018 | $343,000 | +3.9% | 4,839 | -2.6% | 0.01% | -6.7% |
| Q2 2018 | $330,000 | +55.7% | 4,967 | +53.5% | 0.02% | +50.0% |
| Q1 2018 | $212,000 | – | 3,236 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |